Article

Carl Zeiss introduces trifocal IOL

Carl Zeiss Meditec has introduced a trifocal IOL (AT LISA tri 839MP), although it is not available for use in the United States.

Jena, Germany-Carl Zeiss Meditec has introduced a trifocal IOL (AT LISA tri 839MP), although it is not available for use in the United States.

Based on a proprietary platform (AT LISA), the trifocal implant is designed to produce satisfying and predictable visual outcomes, as well as maximized pupil independency, in active patients. The IOL features asymmetrical light distribution between the three different foci: 50% far, 20% intermediate, and 30% near.

According to Carl Zeiss Meditec, the new IOL supports ophthalmologists and ophthalmic surgeons in meeting the demands of patients with cataract and presbyopia who lead active lives and expect surgery to provide them with a quality of vision that is similar to what they were used to before the aging process of their eyes started.

“We would like to assist our customers in optimally addressing the challenges of surgical cataract and presbyopia correction,” said Ludwin Monz, PhD, president and chief executive officer of Carl Zeiss Meditec AG. “With the [new] trifocal IOL, this means that patients are provided with the most natural postoperative vision possible without being reliant on eyeglasses.”

According to Carl Zeiss Meditec, the trifocal IOL can provide enhanced intermediate vision performance with its addition of +1.66 D compared with apodized bifocal or convoluted trifocal IOLs, even under poor light conditions. The pre-loaded implant is suitable for microincision cataract surgery.

For more information, visit www.meditec.zeiss.com/lisa-tri.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.